Growth OpportunitiesLanguage around equipment trends and the outlook on MCS and OPT appear to be improving, ostensibly setting up a better base for growth.

Market RecoveryThere is potential for recovery in the China refractive market with the announced China stimulus.

Bears Say

Financial PerformanceRevenues moved down 9% and EBIT ~42% on a 12-month revised basis, highlighting sensitivity to growth.

Investor ConfidenceVisibility is pretty much at an all-time low, affecting investor confidence.

Market PerformanceThe core lever remains China/APAC refractive which remains subdued, and down on volume, mix (and pricing).

---

Financials

Annual

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.72% Mutual Funds

0.01% Other Institutional Investors

92.96% Public Companies and

Individual Investors

Detailed Ownership Overview >

0DHC FAQ

What was Carl Zeiss Meditec’s price range in the past 12 months?

Carl Zeiss Meditec lowest share price was €45.00 and its highest was €123.30 in the past 12 months.

What is Carl Zeiss Meditec’s market cap?

Currently, no data Available

When is Carl Zeiss Meditec’s upcoming earnings report date?

Carl Zeiss Meditec’s upcoming earnings report date is Feb 12, 2025 which is in 52 days.

How were Carl Zeiss Meditec’s earnings last quarter?

Carl Zeiss Meditec released its earnings results on Dec 11, 2024. The company reported €0.69 earnings per share for the quarter, beating the consensus estimate of €0.538 by €0.152.

Is Carl Zeiss Meditec overvalued?

According to Wall Street analysts Carl Zeiss Meditec’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Carl Zeiss Meditec pay dividends?

Carl Zeiss Meditec pays a Annually dividend of €1.1 which represents an annual dividend yield of 2.41%. See more information on Carl Zeiss Meditec dividends here

What is Carl Zeiss Meditec’s EPS estimate?

Carl Zeiss Meditec’s EPS estimate is €0.27.

How many shares outstanding does Carl Zeiss Meditec have?

Carl Zeiss Meditec has 89,440,570 shares outstanding.

What happened to Carl Zeiss Meditec’s price movement after its last earnings report?

Carl Zeiss Meditec reported an EPS of €0.69 in its last earnings report, beating expectations of €0.538. Following the earnings report the stock price went down -11.317%.

Which hedge fund is a major shareholder of Carl Zeiss Meditec?

Currently, no hedge funds are holding shares in GB:0DHC

---

Carl Zeiss Meditec Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

8.51%

Trailing 12-Months

Asset Growth

13.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Carl Zeiss Meditec

Carl Zeiss Meditec is a Jena, Germany-based manufacturer of ophthalmic devices, such as intraocular lenses, diagnostic equipment, and refractive laser systems, along with optical equipment for microsurgical applications such as neurosurgery. The company now reports in two primary segments, ophthalmic devices (73% of fiscal 2018 revenue) and microsurgery (27%). From a geographic perspective, the firm has a balanced mix of global sales, with 30% derived from Europe, the Middle East, and Africa, 32% from the Americas, and 38% from Asia-Pacific.

---

0DHC Stock 12 Month Forecast

Average Price Target

€60.39

▲(32.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"€39","58":"€58","77":"€77","96":"€96","115":"€115"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€86.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€60.39</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,58,77,96,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.35,60.51538461538462,62.68076923076923,64.84615384615384,67.01153846153846,69.17692307692307,71.34230769230768,73.50769230769231,75.67307692307692,77.83846153846153,80.00384615384615,82.16923076923077,84.33461538461538,{"y":86.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.35,58.50692307692308,58.66384615384616,58.82076923076923,58.97769230769231,59.13461538461539,59.291538461538465,59.44846153846154,59.605384615384615,59.762307692307694,59.91923076923077,60.076153846153844,60.23307692307692,{"y":60.39,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58.35,56.93846153846154,55.526923076923076,54.11538461538461,52.70384615384616,51.292307692307695,49.88076923076923,48.46923076923077,47.05769230769231,45.64615384615385,44.23461538461538,42.823076923076925,41.41153846153846,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":99.3,"date":1703203200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":91.81,"date":1704412800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":100.76,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":114.75,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":106.87,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":98.25,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":85.24,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":65.82,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":62.17,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1725580800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":69.1,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":57.79,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.35,"date":1733443200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Creo Medical

―

PRTC

PureTech Health

―

Compare GB:0DHC Stocks >

Best Analysts Covering 0DHC

1 Year

Anchal VermaJ.P. Morgan

1 Year Success Rate

9/9 ratings generated profit

1 Year Average Return

+34.58%

reiterated a sell rating 12 days ago

Copying Anchal Verma's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +34.58% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Carl Zeiss Meditec (0DHC) Share Price & Analysis

0DHC Stock Chart & Stats

Carl Zeiss Meditec News

Bulls Say, Bears Say

Financials

Options Prices

Ownership Overview

0DHC FAQ

Carl Zeiss Meditec Stock Smart Score

Analyst Consensus

Blogger Sentiment

Technicals

Fundamentals

Company Description

Carl Zeiss Meditec

0DHC Stock 12 Month Forecast

Average Price Target

Technical Analysis

Best Analysts Covering 0DHC

Become an Expert with TipRanks Premium